Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 18, 2020
Daily News
May 18, 2020
- Japan Ethical Drug Sales Down 2.9% in March: Crecon
May 18, 2020
- 7 Japan Major Drug Makers See Limited Impact from COVID-19: FY2019 Earnings
May 18, 2020
- Many Drug Makers Continue Work-from-Home, Voluntary Visit Bans after Govt Partially Lifts COVID-19 Emergency
May 18, 2020
- Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
- Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
May 18, 2020
- Govt Won't Require Fujifilm-Sponsored Trial Data to Approve Avigan for COVID-19: Abe
May 18, 2020
- FPMAJ to Continue COVID-19 Impact Survey on Drug Supplies
May 18, 2020
- Takeda’s Adcetris Gets EU OK for 1st-Line sALCL Treatment in Combo with Chemo
May 18, 2020
- Chugai Licenses Antibody Engineering Technologies to Lilly in COVID-19 Pact
May 18, 2020
- JT Files Riona for Iron Deficiency Anemia in Japan
May 18, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…